Member Info for Walkley

So a few numbers - any better ideas welcome No earnings for 3 years, then profits of $250m in year 4, Year 5: $500m, year 6: $1bn. With a discount rate of 15% (pretty high) Gives NPV of $1.2bn which is about a five times today's market cap.

Whilst RDZ looks as if it is a better mousetrap we will still do better sooner if was pushed to the medical professionals (generally a conservative lot who if they weren't taught about it at medical school...) by a major pharma company. An upfront sale with ongoing royalties must be tempting or at least a joint venture that would allow summit to gain expertise in marketing its drugs.

Back at 250p on Google (last trade) New York opens in just over an hour.

So how should we value Summit now? There will be those long term holders (not to mention Mrs Walkley) tempted to take a profit but surely the current value of £200m is far too low for a company that can produce two major drug programmes each with huge potential. I don't think I will look at selling any until £5. Perhaps the US investors when they wake up will appreciate the significance of a BARDA award - I would imagine that they don't get given out to every new drug programme,.

Yippee!!!

"Should you follow his example and buy Bovis? It’s worth remembering that his remuneration package includes an annual bonus of up to 100% of salary, payable in shares. These ‘free’ shares will lower the average purchase cost of his stockholding considerably, making positive returns far more likely." Fool A ridiculous statement, if Bovis doesn't perform then he wont get the bonus "free" shares and the share price will go down! it is a massive vote of confidence in the company and shows his confidence that he can make a significant difference. if he had doubts he wouldn't have used "real" money to buy shares. What is not to like about these results? I bought for the yield and am getting capital growth as well as the prospect of increased dividends (ordinary and special)

Whilst it is possible for a bigger fish to swallow the whole of Summit I would assume that the people involved would want to keep their independence. As I understand it they will link each programme to a company that that can maximise the potential. Thus Sarepta with their existing DMD programme was a natural fit for Summit's ezutromid and other utrophin modulating drugs. All we need is someone who has a gap in their portfolio for an antibiotic such as ridinilazole and who are prepared to pay both upfront and in royalties to reward Summit for their efforts. As Summit now has cash in the bank they do not need to accept any offer but can hold out for the right one, whilst continuing preparations for the phase 3 trial. Slightly surprised that these are the only programmes we hear about from Summit - I assume there are other possible drugs under development, it would be good to know what areas they are looking at.

Why four ????s -Everyone here is convinced IRON is a bargain. Just need the wider world to notice!

Good to see trades at 209p even if small, also steady progress on Nasdaq -now trading at $14.04 (equivalent to £2.14)

Yes all looking very promising. Am hoping (with nothing to base it on) that a C.diff announcement may be in the offing.

$13.42 in New York with equivalent of 100,000 traded. Equivalent of 206p. Is something happening at last?

Trading update due this week (based on last years timing). Should be very positive.

I cannot find any mention of the D* word anywhere in the results. BTG seems to be becoming mature - their word, some might say ex growth. *Dividend

The boost to the share price is very welcome but we knew this was coming, not sure why it wasn't already in the share price. Enrolling patients is relatively easy - getting the results we all hope for may be more difficult.

IDOX makes money from elections!!

And in mine (humble opinion that is) surely such an outcome deserves a market cap moving towards £80m which would be 25p

RNS is on London Stock Exchange site - LSE hasn't got round to putting it up yet.

Should say Q1

Great news To use an existing smelter - they have bought the company. Will start production earlier than expected in W1 2018. Should boost price today.

Sarepta (market cap $1,580m) is in trouble over claims for its DMD candidate Eteplirsen - Scott + Scott lawyers trying to start a shareholder class action http://tinyurl.com/mykqdtx . Perhaps holders will switch to Summit (market cap $160m)